ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Japan and Western drugmakers launch $1bn fund against superbugs

Takeda, Glaxo and Amgen among 23 names uniting to fight antibiotic resistance

A magnified image of methicillin-resistant Staphylococcus aureus bacteria: drug-resistant diseases kill about 700,000 people a year across the world.   © Reuters

TOKYO -- Drugmakers from Japan, the U.S. and Europe have announced a more than $1 billion fund to invest in startups developing treatments for antibiotic-resistant infections.

The 23 companies include Eisai, Shionogi, Daiichi Sankyo, Takeda Pharmaceutical and Chugai Pharmaceutical from Japan, as well as Amgen and Eli Lilly from the U.S. and Novartis and GlaxoSmithKline from Europe. The World Health Organization and the European Investment Bank also form part of the effort.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more